VEGFR
Vascular endothelial growth factor receptor
VEGFRs consist of three subtypes, the fms-like tyrosine kinase Flt-1 (VEGFR1/Flt-1), the kinase domain region, also referred to as fetal liver kinase (VEGFR2/KDR/Flk-1), and Flt-4 (VEGFR3). Each receptor has seven immunoglobulinlike domains in the extracellular domain, a single transmembrane region, and a consensus tyrosine kinase sequence interrupted by a kinase insert domain. VEGFR1 and 2 are expressed on vascular endothelial cells, whereas VEGFR3 is expressed on lymphatic endothelial. The VEGF family members VEGF-A, -B, -C, -D, -E, and PlGF, and the human immunodeficiency (HIV) Tat protein bind in specific patterns to three related receptor protein tyrosine kinases, VEGFR1, 2, and 3, and induce the formation of homo- and heteromeric receptor complexes. Binding of VEGF to VEGFR causes dimerization and autophosphorylation of the receptor. Intracellular proteins such as VEGFR-associated protein (VRAP), PLC, and Sck that associate with specific tyrosine residues of VEGFR are phosphorylated upon receptor activation. Several signal transduction pathways are activated by the binding of VEGF to its receptor, leading to increased proliferation, survival, permeability, and migration of cells.
VEGFR Isoform Specific Products
All Product Categories
-
VEGFR Inhibitors
(719)
View all products
-
VEGFR Agonists
(7)
View all products
-
VEGFR Antagonists
(6)
View all products
-
VEGFR Activators
(15)
View all products
-
VEGFR Modulators
(6)
View all products
-
VEGFR Chemical
(1)
View all products
-
VEGFR Inducer
(1)
View all products
-
VEGFR Degraders
(4)
View all products
-
VEGFR Ligands
(6)
View all products
-
VEGFR Proteins
(36)
View all products
-
VEGFR-1 Proteins
(10)
View all products
-
VEGFR-3 Proteins
(7)
View all products
-
VEGFR Related Products (811)
Related Products (811)
-
Recombinant Proteins (36)
-
Antibodies (9)
-
VEGFR Isoform Comparison
-
Regorafenib Hydrochloride (Standard)
0 ImagesSynonyms: BAY 73-4506 hydrochloride (Standard)Regorafenib (Hydrochloride) (Standard) is the analytical standard of Regorafenib (Hydrochloride). This product is intended for research and analytical applications. Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
-
Raddeanin A (Standard)
0 ImagesCat. No.: HY-N0819RCAS No.: 89412-79-3Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
-
AFG210
0 ImagesCat. No.: HY-18817CAS No.: 228400-22-4AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC50=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase.
-
Enzyme modulator-1
0 ImagesCat. No.: HY-186223CAS No.: 897375-76-7
-
Ponatinib (Standard)
0 ImagesSynonyms: AP24534 (Standard)Ponatinib (Standard) is the analytical standard of Ponatinib. This product is intended for research and analytical applications. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
-
Ponatinib hydrochloride (Standard)
0 ImagesSynonyms: AP24534 hydrochloride (Standard)Ponatinib (hydrochloride) (Standard) is the analytical standard of Ponatinib (hydrochloride). This product is intended for research and analytical applications. Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
-
K00546 (Standard)
0 ImagesCat. No.: HY-103647RCAS No.: 443798-47-8K00546 (Standard) is the analytical standard of K00546 (HY-103647). This product is intended for research and analytical applications. K00546 is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively.
-
Cediranib (Standard)
0 ImagesSynonyms: AZD2171 (Standard)Cediranib (Standard) is the analytical standard of Cediranib. This product is intended for research and analytical applications. Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
-
Telatinib mesylate (Standard)
0 ImagesSynonyms: Bay 57-9352 mesylate (Standard)Telatinib (mesylate) (Standard) is the analytical standard of Telatinib (mesylate). This product is intended for research and analytical applications. Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2, VEGFR3, PDGFα, and c-Kit inhibitor with IC50s of 6 nM, 4 nM, 15 nM and 1 nM, respectively.
-
ZK-261991
0 ImagesCat. No.: HY-15333CAS No.: 886563-25-3ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC50 of 5 nM for VEGFR2.
-
BMS-690514 (Standard)
0 ImagesCat. No.: HY-10333RCAS No.: 859853-30-8BMS-690514 (Standard) is the analytical standard of BMS-690514 (HY-10333). This product is intended for research and analytical applications. BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR; has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.
-
JK-P3 (Standard)
0 ImagesCat. No.: HY-108933RCAS No.: 942655-44-9JK-P3 (Standard) is the analytical standard of JK-P3 (HY-108933). This product is intended for research and analytical applications. JK-P3 is a potent and pan VEGFR2 inhibitor, with IC50s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor Kinase activity in vitro. JK-P3 has anti-angiogenic activity.
-
ENMD-2076 Tartrate (Standard)
0 ImagesCat. No.: HY-10987RCAS No.: 1453868-32-0ENMD-2076 Tartrate (Standard) is the analytical standard of ENMD-2076 (Tartrate) (HY-10987). This product is intended for research and analytical applications. ENMD-2076 Tartrate is a multi-targeted Kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KdR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
-
Vandetanib trifluoroacetate
0 ImagesCat. No.: HY-10260ACAS No.: 338992-53-3Synonyms: ZD6474 trifluoroacetateVandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib trifluoroacetate also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM).
-
Naphazoline (Standard)
0 ImagesCat. No.: HY-111326RCAS No.: 835-31-4Synonyms: Naphthazoline (Standard)Naphazoline (Standard) is the analytical standard of Naphazoline (HY-111326). This product is intended for research and analytical applications. Naphazoline (Naphthazoline) is a potent α-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytoKines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline can be used for non-bacterial conjunctivitis research.
-
Pazopanib (Standard)
0 ImagesSynonyms: GW786034 (Standard)Pazopanib (Standard) is the analytical standard of Pazopanib. This product is intended for research and analytical applications. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
-
VEGFR2-IN-4
0 ImagesCat. No.: HY-149361CAS No.: 3049398-38-8VEGFR2-IN-4 (compound 25) is a potent and selective VEGFR2 kinase inhibitor, with a GI50 of 0.7 nM. VEGFR2-IN-4 shows anti-angiogenic effect. VEGFR2-IN-4 can be used for the research of rheumatoid arthritis.
-
Motesanib (Standard)
0 ImagesSynonyms: AMG 706 (Standard)Motesanib (Standard) is the analytical standard of Motesanib. This product is intended for research and analytical applications. Motesanib (AMG 706) is a potent ATP-competitive inhibitor of?VEGFR1/2/3?with?IC50s?of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.
-
Lenvatinib N-oxide
0 ImagesCat. No.: HY-135742CAS No.: 1788901-86-9Synonyms: Lenvatinib impurity 10Lenvatinib N-Oxide (Lenvatinib impurity 10) is the impurity of Lenvatinib (HY-10981). Lenvatinib (E7080) is an orally active, multi-targeted tyrosine kinase inhibitor.
-
Ki20227 (Standard)
0 ImagesCat. No.: HY-10408RCAS No.: 623142-96-1Ki20227 (Standard) is the analytical standard of Ki20227 (HY-10408). This product is intended for research and analytical applications. Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.
